HK1246204B - Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol - Google Patents
Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol Download PDFInfo
- Publication number
- HK1246204B HK1246204B HK18105920.4A HK18105920A HK1246204B HK 1246204 B HK1246204 B HK 1246204B HK 18105920 A HK18105920 A HK 18105920A HK 1246204 B HK1246204 B HK 1246204B
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical composition
- pain
- functional
- pharmaceutically acceptable
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15249409P | 2009-02-13 | 2009-02-13 | |
| US152494P | 2009-02-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1246204A1 HK1246204A1 (en) | 2018-09-07 |
| HK1246204B true HK1246204B (en) | 2020-02-07 |
Family
ID=42083967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18105920.4A HK1246204B (en) | 2009-02-13 | 2018-05-08 | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20110301214A1 (enExample) |
| EP (3) | EP2395999B1 (enExample) |
| JP (1) | JP2012518007A (enExample) |
| AU (1) | AU2010213580A1 (enExample) |
| CA (1) | CA2752148A1 (enExample) |
| DK (1) | DK3566703T3 (enExample) |
| ES (3) | ES2649018T3 (enExample) |
| HK (1) | HK1246204B (enExample) |
| WO (1) | WO2010093930A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| JP2013542991A (ja) * | 2010-11-16 | 2013-11-28 | アラーガン インコーポレイテッド | （３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル）メタノールを含む医薬組成物 |
| EP2734200A1 (en) * | 2011-07-22 | 2014-05-28 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| EP4642453A1 (en) * | 2022-12-27 | 2025-11-05 | Alceptor Therapeutics, Inc. | (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol for treatment of agitation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5344840A (en) | 1988-02-29 | 1994-09-06 | Orion-Yhtyma Oy | 4-substituted imidazole derivatives useful in perioperative care |
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| UA78529C2 (en) * | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
| US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| JP2013542991A (ja) | 2010-11-16 | 2013-11-28 | アラーガン インコーポレイテッド | （３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル）メタノールを含む医薬組成物 |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
-
2010
- 2010-02-12 ES ES10706824.9T patent/ES2649018T3/es active Active
- 2010-02-12 AU AU2010213580A patent/AU2010213580A1/en not_active Abandoned
- 2010-02-12 JP JP2011550276A patent/JP2012518007A/ja active Pending
- 2010-02-12 ES ES19168102T patent/ES2880578T3/es active Active
- 2010-02-12 EP EP10706824.9A patent/EP2395999B1/en active Active
- 2010-02-12 ES ES17174959T patent/ES2733905T3/es active Active
- 2010-02-12 EP EP19168102.2A patent/EP3566703B1/en active Active
- 2010-02-12 EP EP17174959.1A patent/EP3241553B1/en active Active
- 2010-02-12 US US13/147,760 patent/US20110301214A1/en not_active Abandoned
- 2010-02-12 WO PCT/US2010/024111 patent/WO2010093930A1/en not_active Ceased
- 2010-02-12 CA CA2752148A patent/CA2752148A1/en not_active Abandoned
- 2010-02-12 DK DK19168102.2T patent/DK3566703T3/da active
-
2014
- 2014-11-21 US US14/550,647 patent/US9193690B2/en active Active
-
2015
- 2015-10-19 US US14/886,457 patent/US9555021B2/en active Active
-
2018
- 2018-05-08 HK HK18105920.4A patent/HK1246204B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9193690B2 (en) | 2015-11-24 |
| ES2880578T3 (es) | 2021-11-24 |
| EP3566703A1 (en) | 2019-11-13 |
| US9555021B2 (en) | 2017-01-31 |
| DK3566703T3 (da) | 2021-07-05 |
| EP3566703B1 (en) | 2021-04-07 |
| EP3241553B1 (en) | 2019-04-10 |
| US20160038466A1 (en) | 2016-02-11 |
| CA2752148A1 (en) | 2010-08-19 |
| EP3241553A1 (en) | 2017-11-08 |
| ES2649018T3 (es) | 2018-01-09 |
| AU2010213580A1 (en) | 2011-09-08 |
| JP2012518007A (ja) | 2012-08-09 |
| EP2395999B1 (en) | 2017-09-13 |
| EP2395999A1 (en) | 2011-12-21 |
| WO2010093930A1 (en) | 2010-08-19 |
| US20110301214A1 (en) | 2011-12-08 |
| US20150080445A1 (en) | 2015-03-19 |
| ES2733905T3 (es) | 2019-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246204B (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| HK1246204A1 (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| US20230062049A1 (en) | Methods of treating alpha adrenergic mediated conditions | |
| CA2744929C (en) | Methods of treating alpha adrenergic mediated conditions | |
| HK40017486B (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| HK40017486A (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| US20080242657A1 (en) | Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists | |
| US20120136035A1 (en) | 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione | |
| IE46709B1 (en) | Antihypertensive compositions | |
| HK1162960A (en) | Methods of treating alpha adrenergic mediated conditions |